KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

TherapeuticsMD (TXMD) Operating Expenses (2016 - 2026)

TherapeuticsMD filings provide 17 years of Operating Expenses readings, the most recent being $1.4 million for Q1 2026.

  • On a quarterly basis, Operating Expenses fell 13.56% to $1.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $7.2 million, a 6.65% decrease, with the full-year FY2025 number at $7.4 million, down 5.86% from a year prior.
  • Operating Expenses hit $1.4 million in Q1 2026 for TherapeuticsMD, down from $2.4 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $20.1 million in Q4 2022 to a low of $1.3 million in Q4 2024.
  • Median Operating Expenses over the past 5 years was $2.1 million (2023), compared with a mean of $5.5 million.
  • Biggest five-year swings in Operating Expenses: skyrocketed 125.87% in 2022 and later tumbled 89.5% in 2023.
  • TherapeuticsMD's Operating Expenses stood at $20.1 million in 2022, then tumbled by 89.5% to $2.1 million in 2023, then crashed by 37.58% to $1.3 million in 2024, then skyrocketed by 85.37% to $2.4 million in 2025, then plummeted by 40.82% to $1.4 million in 2026.
  • The last three reported values for Operating Expenses were $1.4 million (Q1 2026), $2.4 million (Q4 2025), and $1.6 million (Q3 2025) per Business Quant data.